Cancer News: Lung
Researchers have succeeded in amplifying genes altered by activities possibly causing lung cancer such as smoking, enabling deeper analysis of cancer causes.
In a clinical trial, stereotactic body radiation therapy (SBRT) combined with specific chemotherapy improved survival among certain stage 4 lung cancer patients.
The US FDA approved ramucirumab (Cyramza) for the treatment of metastatic non-small-cell lung cancer in combination with docetaxel.
As part of a clinical trial, treatment of a common form of advanced lung cancer with an experimental immunotherapy drug led to promising 1-year survival rate.
According to a study, lung cancers can stay hidden for over 20 years before suddenly "turning on" and revealing themselves as an aggressive form of the disease.
An experimental drug against non-small cell lung cancer with a specific gene (ALK) mutation has been granted "breakthrough therapy" status by the US FDA.
72% of patients with a mutation-specific form of non-small cell lung cancer had an objective response, with median response duration approaching 1.5 years.
A new drug, anamorelin, helps advanced non-small cell lung cancer patients with their appetite and body mass, if they suffer from cancer anorexia and cachexia.
Patients who have non-small cell lung cancer with HER2 mutations may have options for treatment from targeted drugs.
Patients with a mutated subtype of non-small cell lung cancer benefited from a drug in a phase 2 trial presented in the latest oncology conference.
E-cigarettes may not be helping cancer patients to quit smoking, based on a new study.
Aggressive treatment benefits some "low risk" stage 4 non-small cell lung cancer (NSCLC) patients in terms of overall survival.
Advanced small cell lung cancer patients may benefit from radiation combined with conventional treatment in terms of long-term survival and disease recurrence.
Genetic changes can be detected in the vapor given off by cells engineered to mimic the early stages of lung cancer, and could be used to build a breath test.
A study in Norway showed that current X-ray examinations detect only 20% of lung cancer cases. With modern, ultra-low-dose CT scans, this improved to 90%.
Patient-reported outcomes provide valuable insight regarding quality of life for patients with non-small cell lung cancer
An analysis of quality of life (QOL) data of stage III lung cancer patients who received higher doses of radiation therapy (with chemotherapy) shows a significantly lower quality of life at 3 months after treatment compared to patients who received a standard dose of radiation (with chemotherapy), according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.
An experimental Roche drug that seems to work particularly well against lung cancer in smokers may be a "game changer" for these normally difficult-to-treat patients, researchers said on Sunday.
Early data from a small trial of Merck & Co Inc's experimental immunotherapy cancer drug, known as MK-3475, showed that about a quarter of lung cancer patients responded to the treatment.
E-cigarettes, as defined by the FDA, “are battery-operated products designed to deliver nicotine, flavor, and other chemicals. They turn nicotine, which is highly addictive, and other chemicals into a vapor that is inhaled by the user.”
Examining 12 major types of cancer, scientists at Washington University School of Medicine in St. Louis have identified 127 repeatedly mutated genes that appear to drive the development and progression of a range of tumors in the body. The discovery sets the stage for devising new diagnostic tools and more personalized cancer treatments.
The ambitious “Master Protocol” is a collaboration among the lung cancer research community, the National Cancer Institute, the Foundation of the National Institutes of Health, the Food and Drug Administration (FDA), Friends of Cancer Research, and industry.
Genetic testing for personalized treatment of lung cancer was associated with improved survival, likely due to getting targeted kinase inhibitors to the right patients, a study showed.
Results from a recent preclinical study have shown that a new drug combination therapy being developed effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients.
A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one of the most commonly used clinical methods. Whether this reflects a true effect of crizotinib on kidney function, or only on the accuracy of this particular method for assessing it is a topic of ongoing study.
The use of newer stereotactic body radiation therapy (SBRT) appears to give patients with inoperable non-small cell lung cancer significantly improved outcomes when compared with the former technology of choice, conventionally fractioned radiotherapy (CFR), researchers suggested.
Treating people with stereotactic body radiation for suspected -- but unbiopsied -- lung cancers appears to allow for acceptable local control of the disease with low toxicity, researchers reported.
A four-drug combination of cetuximab, bevacizumab, carboplatin, and paclitaxel is effective and has acceptable safety as a first-line treatment for advanced non-small-cell lung cancer (NSCLC), US researchers report.
The total cost of cancer care across the European Union (EU) was an estimated €126 billion (US$ 171.07 billion) in 2009, with lung cancer having the highest cost, at 15% of the total.
Men who continued to smoke after a cancer diagnosis had an increased risk of death compared with those who quit smoking after diagnosis, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
18% of lung cancers identified by low-dose Computed Tomography screening were slow-growing tumors that would not have affected patients during their lifetime.